Press Detail





News: Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept tender offer of CREAT Group

News: Biotest AG / Key word(s): Statement
Biotest AG: Joint reasoned statement of Biotest AG - Management Board and
Supervisory Board recommend to accept tender offer of CREAT Group

01.06.2017 / 10:00
The issuer is solely responsible for the content of this announcement.



/
PRESS RELEASE

Joint reasoned statement of Biotest AG - Management Board and Supervisory
Board recommend to accept tender offer of CREAT Group

Dreieich, 1 June, 2017. Today, the Management Board and Supervisory Board of
Biotest AG published their joint reasoned statement, pursuant to Section 27
of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs-
und Übernahmegesetz - WpÜG), in respect of the offer document published by
Tiancheng (Germany) Pharmaceutical Holdings AG, the bidding company of CREAT
Group, on 18 May 2017.

In this statement, following a due process of review, the Management Board
and Supervisory Board recommend that shareholders accept the offer. This
recommendation is explained in further detail in the joint reasoned
statement.

Following an in-depth appraisal, the Management Board and Supervisory Board
have independently formed the opinion that the consideration offered by the
Bidder is fair within the meaning of Section 31 para. 1 WpÜG and that the
implementation of the Offer is in the interest of Biotest and its
shareholders In assessing the fairness of the offer consideration from a
financial point of view, the Management Board and Supervisory Board were
advised by Credit Suisse, which has issued a written Fairness Opinion in
which it concludes that the offer price for Biotest shareholders is fair to
such shareholders from a financial point of view.

Especially in light of the recent operational challenges and the difficult
transition period during the implementation of the Biotest Next Level (BNL)
strategy, Biotest's Management Board and Supervisory Board welcome Creat's
offer and believe it represents attractive value for shareholders of both
share classes. Together with Creat, Biotest aims to strengthen and expand
its global competitiveness by continuing to develop new products, further
pursuing existing projects such as Biotest Next Level (BNL) as well as by
strengthening its international presence.

The complete joint reasoned statement by the Management Board and the
Supervisory Board of Biotest AG can be accessed via the following link:
http://www.biotest.com/de/en/investor_relations/takeover-offer.cfm

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.




01.06.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de



Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange



End of News DGAP News Service


579439 01.06.2017